The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression

Summary

To measure the effects of Microbial Ecosystem Therapeutics (MET)-2 on symptoms of depression and anxiety using pre- and post-treatment scores for overall depression and anxiety

Timeline

Start

2021-04-01

Primary completion

2021-06

Completion

2021-06

Outcome

Missed primary endpoint

paper however there was no significant difference between placebo and MET-2 groups (p = 0.338). PMID 40116713 ↗

Publications

• Chinna Meyyappan A, Sgarbossa C, Bromley H, Forth E, Muller DJ, Vazquez G, Cabrera C, Milev R. The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression - A Phase 2, Double-Blind, Placebo-Controlled Study: Clinical Results: Innocuite et efficacite du traitement de l'ecosysteme microbien (met-2) dans la depression majeure - une etude de phase 2 a double insu controlee par placebo : resultats cliniques. Can J Psychiatry. 2025 Nov;70(11):816-823. doi: 10.1177/07067437251328270. Epub 2025 Mar 21.
• Chinna Meyyappan A, Sgarbossa C, Vazquez G, Bond DJ, Muller DJ, Milev R. The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression: Protocol for a Phase 2, Double-Blind, Placebo-Controlled Study. JMIR Res Protoc. 2021 Sep 22;10(9):e31439. doi: 10.2196/31439.

Drugs

Indications